Journal of Microbiology and Biotechnology

  • 제31권10호
  • /
  • Pages.1350-1357
  • /
  • 2021
  • /
  • 1017-7825(pISSN)
  • /
  • 1738-8872(eISSN)
한국미생물·생명공학회 (The Korean Society for Microbiology and Biotechnology)
권호 표지
DOI QR코드

DOI QR Code

Isovitexin Is a Direct Inhibitor of Staphylococcus aureus Coagulase

  • Xiang, Hua (College of Animal Medicine, Jilin Agricultural University) ;
  • Yang, Panpan (College of Basic Medical Science, Jilin University) ;
  • Wang, Li (College of Animal Science, Jilin University) ;
  • Li, Jiaxin (College of Animal Science, Jilin University) ;
  • Wang, Tiedong (College of Animal Science, Jilin University) ;
  • Xue, Junze (College of Animal Medicine, Jilin Agricultural University) ;
  • Wang, Dacheng (College of Animal Science, Jilin University) ;
  • Ma, Hongxia (College of Animal Medicine, Jilin Agricultural University)
  • 투고 : 2021.05.11
  • 심사 : 2021.08.17
  • 발행 : 2021.10.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Staphylococcus aureus (S. aureus) is a major pathogen that causes human pneumonia, leading to significant morbidity and mortality. S. aureus coagulase (Coa) triggers the polymerization of fibrin by activating host prothrombin, which then converts fibrinogen to fibrin and contributes to S. aureus pathogenesis and persistent infection. In our research, we demonstrate that isovitexin, an active traditional Chinese medicine component, can inhibit the coagulase activity of Coa but does not interfere with the growth of S. aureus. Furthermore, we show through thermal shift and fluorescence quenching assays that isovitexin directly binds to Coa. Dynamic simulation and structure-activity relationship analyses suggest that V191 and P268 are key amino acid residues responsible for the binding of isovitexin to Coa. Taken together, these data indicate that isovitexin is a direct Coa inhibitor and a promising candidate for drug development against S. aureus infection.

키워드

과제정보

This work was supported by the National Key Research and Development Program of China (2018YFD0500300) and the Science Foundation of Jilin Province, China (No. 20180101276JC).

참고문헌

  1. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG, Jr. 2015. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin. Microbiol. Rev. 28: 603-661. https://doi.org/10.1128/CMR.00134-14
  2. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati M, et al. 2019. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat. Rev. Microbiol. 17: 203-218. https://doi.org/10.1038/s41579-018-0147-4
  3. Assis LM, Nedeljkovic M, Dessen A. 2017. New strategies for targeting and treatment of multi-drug resistant Staphylococcus aureus. Drug Resist. Updat. 31: 1-14. https://doi.org/10.1016/j.drup.2017.03.001
  4. Thammavongsa V, Kim HK, Missiakas D, Schneewind O. 2015. Staphylococcal manipulation of host immune responses. Nat. Rev. Microbiol. 13: 529-543. https://doi.org/10.1038/nrmicro3521
  5. Muhlen S, Dersch P. 2016. Anti-virulence strategies to target bacterial infections. Curr. Top. Microbiol. Immunol. 398: 147-183.
  6. Loeb L. 1903. The influence of certain bacteria on the coagulation of the blood. J. Med. Res. 10: 407-419.
  7. Bjerketorp J, Jacobsson K, Frykberg L. 2004. The von Willebrand factor-binding protein (vWbp) of Staphylococcus aureus is a coagulase. FEMS Microbiol. Lett. 234: 309-314. https://doi.org/10.1016/j.femsle.2004.03.040
  8. Kroh HK, Panizzi P, Bock PE. 2009. Von Willebrand factor-binding protein is a hysteretic conformational activator of prothrombin. Proc. Natl. Acad. Sci. USA 106: 7786-7791. https://doi.org/10.1073/pnas.0811750106
  9. Friedrich R, Panizzi P, Fuentes-Prior P, Richter K, Verhamme I, Anderson PJ, et al. 2003. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425: 535-539. https://doi.org/10.1038/nature01962
  10. Ichinose A. 2012. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int. J. Hematol. 95: 362-370. https://doi.org/10.1007/s12185-012-1064-3
  11. Foster TJ. 2019. The MSCRAMM family of cell-wall-anchored surface proteins of Gram-positive cocci. Trends Microbiol. 27: 927-941. https://doi.org/10.1016/j.tim.2019.06.007
  12. McAdow M, Kim HK, Dedent AC, Hendrickx AP, Schneewind O, Missiakas DM. 2011. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog. 7: e1002307. https://doi.org/10.1371/journal.ppat.1002307
  13. Sawai T, Tomono K, Yanagihara K, Yamamoto Y, Kaku M, Hirakata Y, et al. 1997. Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of Staphylococcus aureus enmeshed in agar beads. Infect. Immun. 65: 466-471. https://doi.org/10.1128/iai.65.2.466-471.1997
  14. Cheng AG, McAdow M, Kim HK, Bae T, Missiakas DM, Schneewind O. 2010. Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog. 6: e1001036. https://doi.org/10.1371/journal.ppat.1001036
  15. Vanassche T, Kauskot A, Verhaegen J, Peetermans WE, van Ryn J, Schneewind O, et al. 2012. Fibrin formation by staphylothrombin facilitates Staphylococcus aureus-induced platelet aggregation. Thromb. Haemost. 107: 1107-1121. https://doi.org/10.1160/TH11-12-0891
  16. Bock PE, Panizzi P, Verhamme IM. 2007. Exosites in the substrate specificity of blood coagulation reactions. J. Thromb. Haemost. 5 Suppl 1: 81-94. https://doi.org/10.1111/j.1538-7836.2007.02496.x
  17. Peetermans M, Verhamme P, Vanassche T. 2015. Coagulase activity by Staphylococcus aureus: a potential target for therapy? Semin. Thromb. Hemost. 41: 433-444. https://doi.org/10.1055/s-0035-1549849
  18. Vanassche T, Verhaegen J, Peetermans WE, Hoylaerts MF, Verhamme P. 2010. Dabigatran inhibits Staphylococcus aureus coagulase activity. J. Clin. Microbiol. 48: 4248-4250. https://doi.org/10.1128/JCM.00896-10
  19. Alatri A, Armstrong AE, Greinacher A, Koster A, Kozek-Langenecker SA, Lance MD, et al. 2012. Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective. Thromb. Res. 129: 426-433. https://doi.org/10.1016/j.thromres.2011.11.041
  20. Lillo-Le Louet A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, et al. 2012. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb. Haemost. 108: 583-585. https://doi.org/10.1160/TH12-03-0149
  21. Zhang H, Jiang JM, Han L, Lao YZ, Zheng D, Chen YY, et al. 2019. Uncariitannin, a polyphenolic polymer from Uncaria gambier, attenuates Staphylococcus aureus virulence through an MgrA-mediated regulation of α-hemolysin. Pharmacol. Res. 147: 104328. https://doi.org/10.1016/j.phrs.2019.104328
  22. Duan J, Li M, Hao Z, Shen X, Liu L, Jin Y, et al. 2018. Subinhibitory concentrations of resveratrol reduce alpha-hemolysin production in Staphylococcus aureus isolates by downregulating saeRS. Emerg. Microbes Infect. 7: 136. https://doi.org/10.1038/s41426-018-0142-x
  23. Wang L, Li B, Si X, Liu X, Deng X, Niu X, et al. 2019. Quercetin protects rats from catheter-related Staphylococcus aureus infections by inhibiting coagulase activity. J. Cell. Mol. Med. 23: 4808-4818. https://doi.org/10.1111/jcmm.14371
  24. He M, Min JW, Kong WL, He XH, Li JX, Peng BW. 2016. A review on the pharmacological effects of vitexin and isovitexin. Fitoterapia 115: 74-85. https://doi.org/10.1016/j.fitote.2016.09.011
  25. Xiao Z, Liu L, Tao W, Pei X, Wang G, Wang M. 2018. Clostridium Tyrobutyricum protect intestinal barrier function from LPS-induced apoptosis via P38/JNK signaling pathway in IPEC-J2 cells. Cell. Physiol. Biochem. 46: 1779-1792. https://doi.org/10.1159/000489364
  26. Hwang SM, Seki K, Sakurada J, Ogasawara M, Murai M, Ohmayu S, et al. 2013. Improved methods for detection and serotyping of coagulase from Staphylococcus aureus. Microbiol. Immunol. 33: 175-182. https://doi.org/10.1111/j.1348-0421.1989.tb01511.x
  27. Krishna SN, Luan CH, Mishra RK, Xu L, Scheidt KA, Anderson WF, et al. 2013. A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4. PLoS One 8: e81504. https://doi.org/10.1371/journal.pone.0081504
  28. Bell L, Bickford S, Nguyen PH, Wang J, He T, Zhang B, et al. 2008. Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery. J. Biomol. Screen. 13: 343-353. https://doi.org/10.1177/1087057108317480
  29. Sok V, Fragoso A. 2018. Kinetic, spectroscopic and computational docking study of the inhibitory effect of the pesticides 2,4,5-T, 2,4-D and glyphosate on the diphenolase activity of mushroom tyrosinase. Int. J. Biol. Macromol. 118: 427-434. https://doi.org/10.1016/j.ijbiomac.2018.06.098
  30. Sanner MF. 1999. Python: a programming language for software integration and development. J. Mol. Graph. Model. 17: 57-61.
  31. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. 2009. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30: 2785-2791. https://doi.org/10.1002/jcc.21256
  32. Pierce LC, Salomon-Ferrer R, Augusto FdOC, McCammon JA, Walker RC. 2012. Routine access to millisecond time scale events with accelerated molecular dynamics. J. Chem. Theory Comput. 8: 2997-3002. https://doi.org/10.1021/ct300284c
  33. Gotz AW, Williamson MJ, Xu D, Poole D, Le Grand S, Walker RC. 2012. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 1. generalized born. J. Chem. Theory Comput. 8: 1542-1555. https://doi.org/10.1021/ct200909j
  34. Salomon-Ferrer R, Gotz AW, Poole D, Le Grand S, Walker RC. 2013. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle Mesh Ewald. J. Chem. Theory Comput. 9: 3878-3888. https://doi.org/10.1021/ct400314y
  35. Tam K, Torres VJ. 2019. Staphylococcus aureus secreted toxins and extracellular enzymes. Microbiol. Spectr. 7: 10.1128/microbiolspec.GPP3-0039-2018.
  36. Kong C, Neoh HM, Nathan S. 2016. Targeting Staphylococcus aureus toxins: a potential form of anti-virulence therapy. Toxins 8: 72. https://doi.org/10.3390/toxins8030072
  37. Gao Z, Luan Y, Yang P, Wang L, Zhang H, Jing S, et al. 2020. Targeting staphylocoagulase with isoquercitrin protects mice from Staphylococcus aureus-induced pneumonia. Appl. Microbiol. Biotechnol. 104: 3909-3919. https://doi.org/10.1007/s00253-020-10486-2
  38. Boufridi A, Quinn RJ. 2018. Harnessing the properties of natural products. Annu. Rev. Pharmacol. Toxicol. 58: 451-470. https://doi.org/10.1146/annurev-pharmtox-010716-105029
  39. Zhang H, Luan Y, Jing S, Wang Y, Gao Z, Yang P, et al. 2020. Baicalein mediates protection against Staphylococcus aureus-induced pneumonia by inhibiting the coagulase activity of vWbp. Biochem. Pharmacol. 178: 114024. https://doi.org/10.1016/j.bcp.2020.114024
  40. Hwang SM, Seki K, Sakurada J, Ogasawara M, Murai M, Ohmayu S, et al. 1989. Improved methods for detection and serotyping of coagulase from Staphylococcus aureus. Microbiol. Immunol. 33: 175-182. https://doi.org/10.1111/j.1348-0421.1989.tb01511.x